EyeGate Pharmaceuticals

EyeGate Pharmaceuticals is a clinical-stage specialty pharmaceutical company based in Waltham, Massachusetts. The company employs 21 people and generates $5 million in annual revenue. EyeGate is traded on the Nasdaq Capital Market under the symbol EYEG. EyeGate Pharmaceuticals develops and commercializes innovative products for treating diseases and disorders of the eye. Their primary focus lies in utilizing two proprietary platform technologies. One platform utilizes a modified form of hyaluronic acid, CMHA-S, to create a gel that promotes healing and lubrication for the ocular surface. Their first product candidate, EyeGate Ocular Bandage Gel (OBG), utilizes this technology and has completed its first-in-man clinical trial for healing and lubricating large epithelial defects after PRK surgery. The second platform involves an innovative iontophoresis drug delivery system, the EyeGate® II Delivery System, which delivers topically active corticosteroids directly into ocular tissues. Their initial product candidate using this platform, EGP-437, is currently in clinical development for treating various inflammatory eye conditions, such as post-surgical inflammation and pain after cataract surgery, as well as uveitis. EyeGate's EyeGate® II Delivery System has been utilized in over 2,400 treatments across various clinical trials. The company has also entered into exclusive, worldwide licensing agreements with subsidiaries of Valeant Pharmaceuticals International, granting them commercial and manufacturing rights for EGP-437 in treating uveitis and post-operative ocular inflammation and pain. For more information on EyeGate Pharmaceuticals and its products, please visit their website at eyegatepharma.com.